ES2970378T3 - Compuesto y composición para inducir la neuroprotección - Google Patents

Compuesto y composición para inducir la neuroprotección Download PDF

Info

Publication number
ES2970378T3
ES2970378T3 ES21734182T ES21734182T ES2970378T3 ES 2970378 T3 ES2970378 T3 ES 2970378T3 ES 21734182 T ES21734182 T ES 21734182T ES 21734182 T ES21734182 T ES 21734182T ES 2970378 T3 ES2970378 T3 ES 2970378T3
Authority
ES
Spain
Prior art keywords
oxazaphosphinane
tetramethyl
oxo
compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21734182T
Other languages
English (en)
Spanish (es)
Inventor
Gilles Rubinstenn
Tangui Maurice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
University of Montpellier
École Pratique des Hautes Études
ReST Therapeutics SAS
Original Assignee
Institut National de la Santé et de la Recherche Médicale
University of Montpellier
École Pratique des Hautes Études
ReST Therapeutics SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73013493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2970378(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institut National de la Santé et de la Recherche Médicale, University of Montpellier, École Pratique des Hautes Études, ReST Therapeutics SAS filed Critical Institut National de la Santé et de la Recherche Médicale
Application granted granted Critical
Publication of ES2970378T3 publication Critical patent/ES2970378T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES21734182T 2020-05-20 2021-05-20 Compuesto y composición para inducir la neuroprotección Active ES2970378T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2005138A FR3110393B1 (fr) 2020-05-20 2020-05-20 Compose et composition pour induire une neuroprotection
PCT/FR2021/050929 WO2021234324A1 (fr) 2020-05-20 2021-05-20 Compose et composition pour induire une neuroprotection

Publications (1)

Publication Number Publication Date
ES2970378T3 true ES2970378T3 (es) 2024-05-28

Family

ID=73013493

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21734182T Active ES2970378T3 (es) 2020-05-20 2021-05-20 Compuesto y composición para inducir la neuroprotección

Country Status (9)

Country Link
US (1) US12611387B2 (cg-RX-API-DMAC7.html)
EP (1) EP4142703B8 (cg-RX-API-DMAC7.html)
JP (1) JP2023531869A (cg-RX-API-DMAC7.html)
KR (1) KR20230013116A (cg-RX-API-DMAC7.html)
CN (1) CN116981449A (cg-RX-API-DMAC7.html)
CA (1) CA3178633A1 (cg-RX-API-DMAC7.html)
ES (1) ES2970378T3 (cg-RX-API-DMAC7.html)
FR (1) FR3110393B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021234324A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3149773B1 (fr) 2023-06-19 2026-04-17 Rest Therapeutics Nouvelles combinaisons synergiques a base de fenm
FR3163834A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine
WO2026003229A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine pour leur utilisation en tant que medicament
FR3163835B1 (fr) 2024-06-26 2026-06-26 Rest Therapeutics Derives de fluoroethylnormemantine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
BRPI0516112A (pt) * 2004-10-15 2008-08-26 Janssen Pharmaceutica Nv métodos para neuroproteção
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20120115943A1 (en) * 2008-10-01 2012-05-10 National Taiwan University Composition and method for neuroprotection against excitotoxic injury
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
FR3006193B1 (fr) * 2013-05-29 2015-06-19 Holis Technologies Nouveaux composes chimiques derives de la memantine et susceptibles de se fixer sur les recepteurs de n-methyl-d-aspartate (nmda)
FR3050732B1 (fr) 2016-05-02 2019-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
WO2020232246A1 (en) * 2019-05-15 2020-11-19 The Trustees Of Columbia University In The City Of New York Compositions and methods against stress-induced affective disorders and their associated symptoms

Also Published As

Publication number Publication date
FR3110393A1 (fr) 2021-11-26
EP4142703B8 (fr) 2023-11-22
EP4142703A1 (fr) 2023-03-08
CA3178633A1 (fr) 2021-11-25
CN116981449A (zh) 2023-10-31
EP4142703C0 (fr) 2023-10-18
WO2021234324A1 (fr) 2021-11-25
US12611387B2 (en) 2026-04-28
EP4142703B1 (fr) 2023-10-18
KR20230013116A (ko) 2023-01-26
FR3110393B1 (fr) 2022-05-06
JP2023531869A (ja) 2023-07-26
US20230270695A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
Wollenberg et al. Atopic dermatitis in children and adults: diagnosis and treatment
US12611387B2 (en) Compound and composition for inducing neuroprotection
ES2742728T3 (es) Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
ES2930628T3 (es) Uso de pridopidina para mejorar la memoria
ES2450074T3 (es) Terapia para trastornos neurológicos basada en baclofeno y acamprosato
ES2726223T3 (es) Composiciones que comprenden ketamina para el tratamiento de un trastorno del espectro autista
Companys-Alemany et al. NMDA receptor antagonists reduce amyloid-β deposition by modulating calpain-1 signaling and autophagy, rescuing cognitive impairment in 5XFAD mice
Lin et al. Tanshinone IIA ameliorates spatial learning and memory deficits by inhibiting the activity of ERK and GSK-3β
ES2675544T3 (es) Tratamiento para trastornos mentales y neurológicos
ES2972205T3 (es) Pridopidina para el tratamiento del síndrome x frágil
Huang et al. Modulating the balance of synaptic and extrasynaptic NMDA receptors shows positive effects against amyloid-β-induced neurotoxicity
JP6379113B2 (ja) 免疫グロブリンgの鼻腔内投与による中枢神経系障害の治療
US9974801B2 (en) Methods of treating and preventing diseases and disorders of the central nervous system
Liu et al. Environmental enrichment mitigates deficits after repetitive mild traumatic brain injury
Liu et al. Bexarotene attenuates focal cerebral ischemia–reperfusion injury via the suppression of JNK/Caspase-3 signaling pathway
Li et al. Breviscapine exerts neuroprotective effects through multiple mechanisms in APP/PS1 transgenic mice
ES2750839T3 (es) Composición farmacéutica para la prevención, tratamiento o retraso de la enfermedad de Alzheimer o demencia que contiene agente receptor acoplado a proteína G 19 como ingrediente activo
Tan et al. Tauopathies: mechanisms and therapeutic strategies
Shan et al. A long-acting lyotropic liquid crystalline implant promotes the drainage of macromolecules by brain-related lymphatic system in treating aged Alzheimer’s disease
Hsueh et al. (-)-Phenserine ameliorates contusion volume, neuroinflammation, and behavioral impairments induced by traumatic brain injury in mice
ES3056138T3 (en) Methods of treating the symptoms of autism spectrum disorder
Park et al. Influence of mild traumatic brain injury during pediatric stage on short-term memory and hippocampal apoptosis in adult rats
Liao et al. Osteopontin-integrin signaling positively regulates neuroplasticity through enhancing neural autophagy in the peri-infarct area after ischemic stroke
AU2015254661A9 (en) Treatment and prevention of Alzheimer's Disease (AD)
US11065273B2 (en) Treatment and prevention of alzheimer's disease (AD)